Role of the TMPRSS2-ERG gene fusion in prostate cancer

Scott A. Tomlins, Bharathi Laxman, Sooryanarayana Varambally, Xuhong Cao, Jindan Yu, Beth E. Helgeson, Qi Cao, John R. Prensner, Mark A. Rubin, Rajal B. Shah, Rohit Mehra, Arul M. Chinnaiyan

Research output: Contribution to journalArticle

435 Citations (Scopus)

Abstract

TMPRSS2-ERG gene fusions are the predominant molecular subtype of prostate cancer. Here, we explored the role of TMPRSS2-ERG gene fusion product using in vitro and in vivo model systems. Transgenic mice expressing the ERG gene fusion product under androgen-regulation develop mouse prostatic intraepithelial neoplasia (PIN), a precursor lesion of prostate cancer. Introduction of the ERG gene fusion product into primary or immortalized benign prostate epithelial cells induced an invasion-associated transcriptional program but did not increase cellular proliferation or anchorage-independent growth. These results suggest that TMPRSS2-ERG may not be sufficient for transformation in the absence of secondary molecular lesions. Transcriptional profiling of ERG knockdown in the TMPPRSS2-ERG-positive prostate cancer cell line VCaP revealed decreased expression of genes over-expressed in prostate cancer versus PIN and genes overexpressed in ETS-positive versus -negative prostate cancers in addition to inhibiting invasion. ERG knockdown in VCaP cells also induced a transcriptional program consistent with prostate differentiation. Importantly, VCaP cells and benign prostate cells overexpressing ERG directly engage components of the plasminogen activation pathway to mediate cellular invasion, potentially representing a downstream ETS target susceptible to therapeutic intervention. Our results support previous work suggesting that TMPRSS2-ERG fusions mediate invasion, consistent with the defining histologic distinction between PIN and prostate cancer.

Original languageEnglish (US)
Pages (from-to)177-188
Number of pages12
JournalNeoplasia
Volume10
Issue number2
DOIs
StatePublished - Feb 2008
Externally publishedYes

Fingerprint

Gene Fusion
Prostatic Neoplasms
Prostatic Intraepithelial Neoplasia
Prostate
Plasminogen
Transgenic Mice
Androgens
Epithelial Cells
Cell Proliferation
Gene Expression
Cell Line
Growth
Genes

ASJC Scopus subject areas

  • Cancer Research

Cite this

Tomlins, S. A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B. E., ... Chinnaiyan, A. M. (2008). Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia, 10(2), 177-188. https://doi.org/10.1593/neo.07822

Role of the TMPRSS2-ERG gene fusion in prostate cancer. / Tomlins, Scott A.; Laxman, Bharathi; Varambally, Sooryanarayana; Cao, Xuhong; Yu, Jindan; Helgeson, Beth E.; Cao, Qi; Prensner, John R.; Rubin, Mark A.; Shah, Rajal B.; Mehra, Rohit; Chinnaiyan, Arul M.

In: Neoplasia, Vol. 10, No. 2, 02.2008, p. 177-188.

Research output: Contribution to journalArticle

Tomlins, SA, Laxman, B, Varambally, S, Cao, X, Yu, J, Helgeson, BE, Cao, Q, Prensner, JR, Rubin, MA, Shah, RB, Mehra, R & Chinnaiyan, AM 2008, 'Role of the TMPRSS2-ERG gene fusion in prostate cancer', Neoplasia, vol. 10, no. 2, pp. 177-188. https://doi.org/10.1593/neo.07822
Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008 Feb;10(2):177-188. https://doi.org/10.1593/neo.07822
Tomlins, Scott A. ; Laxman, Bharathi ; Varambally, Sooryanarayana ; Cao, Xuhong ; Yu, Jindan ; Helgeson, Beth E. ; Cao, Qi ; Prensner, John R. ; Rubin, Mark A. ; Shah, Rajal B. ; Mehra, Rohit ; Chinnaiyan, Arul M. / Role of the TMPRSS2-ERG gene fusion in prostate cancer. In: Neoplasia. 2008 ; Vol. 10, No. 2. pp. 177-188.
@article{c2240968c2b44103a63f22e6733fddce,
title = "Role of the TMPRSS2-ERG gene fusion in prostate cancer",
abstract = "TMPRSS2-ERG gene fusions are the predominant molecular subtype of prostate cancer. Here, we explored the role of TMPRSS2-ERG gene fusion product using in vitro and in vivo model systems. Transgenic mice expressing the ERG gene fusion product under androgen-regulation develop mouse prostatic intraepithelial neoplasia (PIN), a precursor lesion of prostate cancer. Introduction of the ERG gene fusion product into primary or immortalized benign prostate epithelial cells induced an invasion-associated transcriptional program but did not increase cellular proliferation or anchorage-independent growth. These results suggest that TMPRSS2-ERG may not be sufficient for transformation in the absence of secondary molecular lesions. Transcriptional profiling of ERG knockdown in the TMPPRSS2-ERG-positive prostate cancer cell line VCaP revealed decreased expression of genes over-expressed in prostate cancer versus PIN and genes overexpressed in ETS-positive versus -negative prostate cancers in addition to inhibiting invasion. ERG knockdown in VCaP cells also induced a transcriptional program consistent with prostate differentiation. Importantly, VCaP cells and benign prostate cells overexpressing ERG directly engage components of the plasminogen activation pathway to mediate cellular invasion, potentially representing a downstream ETS target susceptible to therapeutic intervention. Our results support previous work suggesting that TMPRSS2-ERG fusions mediate invasion, consistent with the defining histologic distinction between PIN and prostate cancer.",
author = "Tomlins, {Scott A.} and Bharathi Laxman and Sooryanarayana Varambally and Xuhong Cao and Jindan Yu and Helgeson, {Beth E.} and Qi Cao and Prensner, {John R.} and Rubin, {Mark A.} and Shah, {Rajal B.} and Rohit Mehra and Chinnaiyan, {Arul M.}",
year = "2008",
month = "2",
doi = "10.1593/neo.07822",
language = "English (US)",
volume = "10",
pages = "177--188",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Role of the TMPRSS2-ERG gene fusion in prostate cancer

AU - Tomlins, Scott A.

AU - Laxman, Bharathi

AU - Varambally, Sooryanarayana

AU - Cao, Xuhong

AU - Yu, Jindan

AU - Helgeson, Beth E.

AU - Cao, Qi

AU - Prensner, John R.

AU - Rubin, Mark A.

AU - Shah, Rajal B.

AU - Mehra, Rohit

AU - Chinnaiyan, Arul M.

PY - 2008/2

Y1 - 2008/2

N2 - TMPRSS2-ERG gene fusions are the predominant molecular subtype of prostate cancer. Here, we explored the role of TMPRSS2-ERG gene fusion product using in vitro and in vivo model systems. Transgenic mice expressing the ERG gene fusion product under androgen-regulation develop mouse prostatic intraepithelial neoplasia (PIN), a precursor lesion of prostate cancer. Introduction of the ERG gene fusion product into primary or immortalized benign prostate epithelial cells induced an invasion-associated transcriptional program but did not increase cellular proliferation or anchorage-independent growth. These results suggest that TMPRSS2-ERG may not be sufficient for transformation in the absence of secondary molecular lesions. Transcriptional profiling of ERG knockdown in the TMPPRSS2-ERG-positive prostate cancer cell line VCaP revealed decreased expression of genes over-expressed in prostate cancer versus PIN and genes overexpressed in ETS-positive versus -negative prostate cancers in addition to inhibiting invasion. ERG knockdown in VCaP cells also induced a transcriptional program consistent with prostate differentiation. Importantly, VCaP cells and benign prostate cells overexpressing ERG directly engage components of the plasminogen activation pathway to mediate cellular invasion, potentially representing a downstream ETS target susceptible to therapeutic intervention. Our results support previous work suggesting that TMPRSS2-ERG fusions mediate invasion, consistent with the defining histologic distinction between PIN and prostate cancer.

AB - TMPRSS2-ERG gene fusions are the predominant molecular subtype of prostate cancer. Here, we explored the role of TMPRSS2-ERG gene fusion product using in vitro and in vivo model systems. Transgenic mice expressing the ERG gene fusion product under androgen-regulation develop mouse prostatic intraepithelial neoplasia (PIN), a precursor lesion of prostate cancer. Introduction of the ERG gene fusion product into primary or immortalized benign prostate epithelial cells induced an invasion-associated transcriptional program but did not increase cellular proliferation or anchorage-independent growth. These results suggest that TMPRSS2-ERG may not be sufficient for transformation in the absence of secondary molecular lesions. Transcriptional profiling of ERG knockdown in the TMPPRSS2-ERG-positive prostate cancer cell line VCaP revealed decreased expression of genes over-expressed in prostate cancer versus PIN and genes overexpressed in ETS-positive versus -negative prostate cancers in addition to inhibiting invasion. ERG knockdown in VCaP cells also induced a transcriptional program consistent with prostate differentiation. Importantly, VCaP cells and benign prostate cells overexpressing ERG directly engage components of the plasminogen activation pathway to mediate cellular invasion, potentially representing a downstream ETS target susceptible to therapeutic intervention. Our results support previous work suggesting that TMPRSS2-ERG fusions mediate invasion, consistent with the defining histologic distinction between PIN and prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=39049150843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049150843&partnerID=8YFLogxK

U2 - 10.1593/neo.07822

DO - 10.1593/neo.07822

M3 - Article

C2 - 18283340

AN - SCOPUS:39049150843

VL - 10

SP - 177

EP - 188

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 2

ER -